Eris Lifesciences growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+8.2%+22.9%
EBITDA+10.1%+27.8%
Net Income+72.9%+20.1%
EPS (adj.)+76.1%+17.5%
Total Assets+4.7%+26.2%
Total Equity+19.1%+20.6%
Free Cash Flow−73.5%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ERIS₹1,163.60

Eris Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersMANKINDAJANTPHARMTORNTPHARMEMCUREGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹16,116 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+8.2+22.9
EBITDA+10.1+27.8
Net Income+72.9+20.1
EPS (adj.)+76.1+17.5
Total Assets+4.7+26.2
Total Equity+19.1+20.6
Free Cash Flow-73.5—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.